Kraig Biocraft Laboratories, Inc.

KBLB

US50075W1045

Specialty Chemicals

Market Closed - OTC Markets Other stock markets 20:54:42 26/06/2024 BST			5-day change	1st Jan Change
0.1462 ^USD	+0.83%		-1.68%	+277.78%

06-17	Kraig Biocraft Laboratories, Inc. Successfully Completes Cocooning in First Commercial Production Run of BAM-1 Spider Silk Hybrids	CI
06-11	Kraig Biocraft Laboratories Announces Production Update for BAM-1 Spider Silk Hybrids	CI

Kraig Biocraft Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 14, 2024 at 09:31 pm

Kraig Biocraft Laboratories, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 0.507875 million compared to USD 0.566782 million a year ago.

Latest news about Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. Successfully Completes Cocooning in First Commercial Production Run of BAM-1 Spider Silk Hybrids	06-17	CI
Kraig Biocraft Laboratories Announces Production Update for BAM-1 Spider Silk Hybrids	06-11	CI
Kraig Biocraft Laboratories, Inc. Announces BAM-1 Spider Silk Hybrids Are in Production	06-03	CI
Kraig Biocraft Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Kraig Biocraft Laboratories, Inc. Spring Spider Silk Production Trials Exceed Expectations	05-09	CI
Kraig Biocraft Laboratories, Inc. Reports Signing Agreements in South East Asia	04-29	CI
Kraig Biocraft Laboratories, Inc. Successfully Completes Recombinant Cocoon Production from Spring Trials	04-22	CI
Kraig Biocraft Laboratories Signs Agreement in Vietnam's Silk Production Capital	04-08	CI
Kraig Biocraft Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Kraig Biocraft Laboratories, Inc. Provides Update on Launch of Spring Trials	03-12	CI
Kraig Biocraft Laboratories, Inc. Announces New Premium Spider Silk and Pima Cotton Composite Yarn	02-20	CI
Kraig Biocraft Laboratories, Inc. Announces New Spider Silk Production Facility in Vietnam's Silk Capital	02-13	CI
Kraig Biocraft Laboratories, Inc. Announces the Successful Creation of A New Recombinant Spider Silk Hybrid	02-06	CI
Kraig Biocraft Laboratories, Inc. Announces Early Start to Production Season with Successful Small Batch Delivery of Spider Silk	12-14	CI
Kraig Biocraft Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Kraig Biocraft Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Kraig Biocraft Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Kraig Biocraft Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	29/03/23	CI
Kraig Biocraft Laboratories, Inc. Auditor Raises 'Going Concern' Doubt	28/03/23	CI
Kraig Biocraft Laboratories Delivers the First Two Hybrid Dragon Silk™ Silkworm Strains for Commercial Production	26/01/23	CI
Kraig Biocraft Laboratories, Inc. announced that it has received $8 million in funding from Yorkville Advisors Global LP	14/11/22	CI
Kraig Biocraft Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Kraig Biocraft Laboratories Expands Operational Footprint in Vietnam	17/08/22	CI
Kraig Biocraft Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	01/08/22	CI
Kraig Biocraft Laboratories Introduces New, Enhanced Line of Dragon Silk™ Silkworms for Commercial Production	06/07/22	CI

Chart Kraig Biocraft Laboratories, Inc.

Duration

Period

More charts

Company Profile

Kraig Biocraft Laboratories, Inc. develops fibers using recombinant deoxyribonucleic acid (DNA) technology for commercial applications in technical textiles. The Company uses genetically engineered silkworms that produce spider silk proteins to create its recombinant spider silk. Its primary fiber technology includes natural and engineered variants of spider silk produced from domesticated mulberry silkworms. The Companyâs products use the characteristics of spider silk, specifically dragline silk from Nephila clavipes and variants thereof. Its recombinant spider silk fiber blends the silk proteins found in spider silk with the native silkworm silk proteins. Its products include Monster Silk, Dragon Silk, and other products. Its applications include performance apparel, workwear, filtration, luxury fashion, flexible composites, medical implants, cosmetics and more. The Company also focuses on developing various recombinant silks and other protein-based fibers and materials.

Sector

Specialty Chemicals

More about the company

Income Statement Evolution

More financial data

Sector Other Specialty Chemicals

	1st Jan change	Capi.
KRAIG BIOCRAFT LABORATORIES, INC.	+277.78%	151M
ECOLAB INC.	+21.33%	68.87B
SIKA AG	-5.01%	46.12B
GIVAUDAN SA	+24.57%	44.85B
FUJIFILM HOLDINGS CORPORATION	+30.69%	27.9B
EMS-CHEMIE HOLDING AG	+8.44%	19.38B
SYMRISE AG	+16.07%	17.2B
CELANESE CORPORATION	-10.88%	14.68B
POSCO FUTURE M CO., LTD.	-29.11%	14.14B
NITTO DENKO CORPORATION	+20.66%	11.33B